It's a point well taken.
Thank you.
Harmonization has consequences. I want to come back to the pharmaceutical sector because it has an important role in my community.
Some studies report that extending IP rights to meet EU requirements would increase health spending by some $2.8 billion a year, because generic drugs would come onto the market later, as a result. You may already be aware of that argument, but I would like to hear your thoughts on that point. Extending patent protection, for example, may have repercussions on drug prices.